Joanna Saleh, Wasim S. El Nekidy, Mohamed Hisham, Hazem Elrefaei, Emna Abidi, Malak AlTakruri, Oussama Kalagieh, Salma Alzaabi, Bassam Atallah, Omar Chehab, Rami Ismail, Saad Sultan
{"title":"药剂师主导的护理过渡模式对一家四级护理医院住院时间和 30 天再入院率的影响:试点研究","authors":"Joanna Saleh, Wasim S. El Nekidy, Mohamed Hisham, Hazem Elrefaei, Emna Abidi, Malak AlTakruri, Oussama Kalagieh, Salma Alzaabi, Bassam Atallah, Omar Chehab, Rami Ismail, Saad Sultan","doi":"10.1016/j.japhpi.2024.100015","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Data about the impact of pharmacist-led transitions of care (TOC) approach are not well established.</p></div><div><h3>Objectives</h3><p>The objective of this pilot study was to evaluate the impact of pharmacist-led TOC enhanced workflow on the length of hospital stay (LOS) and the 30-day hospital readmission rates (HRRs).</p></div><div><h3>Methods</h3><p>This is a quality improvement pilot project conducted at a quaternary care hospital in the United Arab Emirates over 6 weeks on a medical floor and 4 weeks on a cardiac floor. TOC was defined as admission medication reconciliation (AMR) and discharge medication reconciliation (DMR).</p></div><div><h3>Results</h3><p>The median LOS was statistically significantly lower in patients who received AMR on the medical floor (4 days [3-8]) than those who did not (7 days [4-20]) (<em>P</em> < 0.001). The median LOS on the cardiac floor was not statistically significantly affected—3 (1.75-8) versus 3 (1-8) (<em>P</em> = 0.736). However, the multivariate linear regression model, adjusting for the number of interventions, indicated that LOS was statistically significantly lower on both floors; AMR was an independent risk factor for reducing the LOS on the medical floor (B = −8.37 [95 CI −11.37 to −5.36], <em>P</em> = .001) and on the cardiac floor (B = −2.76 [95% CI −5.23 to −0.28], <em>P</em> = 0.029). The 30-day HRR was not different on the medical floor but was numerically lower on the cardiac floor in patients who received DMR alone (12.9%) than in those who did not (17.2%) (<em>P</em> = 0.476). However, the multivariate logistic regression analysis, adjusting for number of interventions, indicated that the pharmacist-led AMR and DMR combined were numerically associated with lower rates of 30-day HRR with respective odds ratios of 0.64 (95% CI 0.3–1.38) and 0.83 (95% CI 0.4–1.9) (<em>P</em> = 0.83) on the medical floor and of 0.96 (95% CI 0.3–2.6) and 0.7 (95% CI 0.3–1.8) (<em>P</em> = 0.28) on the cardiac floor. In addition, the impact of the described pharmacist-led TOC approach on health care costs at the hospital was quantifiable and reflected a median medications utilization cost of $1142.95 (639.69-2444.88) when TOC is performed versus $1371.54 (402.92-4277.39) without TOC (<em>P</em> < 0.001) on the medical floor and of $4728.98 (2436.66-6846.34) versus $5252.79 (3907.63-7784.57) (<em>P</em> < 0.001) on the cardiac floor throughout the study time period.</p></div><div><h3>Conclusion</h3><p>Pharmacist-led TOC interventions, specifically AMR, significantly reduced the LOS on the medical and the cardiac floors, whereas both AMR and DMR represented promising predictors of decreased 30-day HRR on the studied floors. Furthermore, the TOC interventions were generally associated with a statistically significant financial impact on both studied floors.</p></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"1 4","pages":"Article 100015"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949969024000083/pdfft?md5=2c847fbe9649dca2c6a23f0fd97e8592&pid=1-s2.0-S2949969024000083-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of pharmacist-led transitions of care model on length of hospital stay and 30-day readmission rates at a quaternary care hospital: A pilot study\",\"authors\":\"Joanna Saleh, Wasim S. El Nekidy, Mohamed Hisham, Hazem Elrefaei, Emna Abidi, Malak AlTakruri, Oussama Kalagieh, Salma Alzaabi, Bassam Atallah, Omar Chehab, Rami Ismail, Saad Sultan\",\"doi\":\"10.1016/j.japhpi.2024.100015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Data about the impact of pharmacist-led transitions of care (TOC) approach are not well established.</p></div><div><h3>Objectives</h3><p>The objective of this pilot study was to evaluate the impact of pharmacist-led TOC enhanced workflow on the length of hospital stay (LOS) and the 30-day hospital readmission rates (HRRs).</p></div><div><h3>Methods</h3><p>This is a quality improvement pilot project conducted at a quaternary care hospital in the United Arab Emirates over 6 weeks on a medical floor and 4 weeks on a cardiac floor. TOC was defined as admission medication reconciliation (AMR) and discharge medication reconciliation (DMR).</p></div><div><h3>Results</h3><p>The median LOS was statistically significantly lower in patients who received AMR on the medical floor (4 days [3-8]) than those who did not (7 days [4-20]) (<em>P</em> < 0.001). The median LOS on the cardiac floor was not statistically significantly affected—3 (1.75-8) versus 3 (1-8) (<em>P</em> = 0.736). However, the multivariate linear regression model, adjusting for the number of interventions, indicated that LOS was statistically significantly lower on both floors; AMR was an independent risk factor for reducing the LOS on the medical floor (B = −8.37 [95 CI −11.37 to −5.36], <em>P</em> = .001) and on the cardiac floor (B = −2.76 [95% CI −5.23 to −0.28], <em>P</em> = 0.029). The 30-day HRR was not different on the medical floor but was numerically lower on the cardiac floor in patients who received DMR alone (12.9%) than in those who did not (17.2%) (<em>P</em> = 0.476). However, the multivariate logistic regression analysis, adjusting for number of interventions, indicated that the pharmacist-led AMR and DMR combined were numerically associated with lower rates of 30-day HRR with respective odds ratios of 0.64 (95% CI 0.3–1.38) and 0.83 (95% CI 0.4–1.9) (<em>P</em> = 0.83) on the medical floor and of 0.96 (95% CI 0.3–2.6) and 0.7 (95% CI 0.3–1.8) (<em>P</em> = 0.28) on the cardiac floor. In addition, the impact of the described pharmacist-led TOC approach on health care costs at the hospital was quantifiable and reflected a median medications utilization cost of $1142.95 (639.69-2444.88) when TOC is performed versus $1371.54 (402.92-4277.39) without TOC (<em>P</em> < 0.001) on the medical floor and of $4728.98 (2436.66-6846.34) versus $5252.79 (3907.63-7784.57) (<em>P</em> < 0.001) on the cardiac floor throughout the study time period.</p></div><div><h3>Conclusion</h3><p>Pharmacist-led TOC interventions, specifically AMR, significantly reduced the LOS on the medical and the cardiac floors, whereas both AMR and DMR represented promising predictors of decreased 30-day HRR on the studied floors. Furthermore, the TOC interventions were generally associated with a statistically significant financial impact on both studied floors.</p></div>\",\"PeriodicalId\":100737,\"journal\":{\"name\":\"JAPhA Practice Innovations\",\"volume\":\"1 4\",\"pages\":\"Article 100015\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949969024000083/pdfft?md5=2c847fbe9649dca2c6a23f0fd97e8592&pid=1-s2.0-S2949969024000083-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAPhA Practice Innovations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949969024000083\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPhA Practice Innovations","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949969024000083","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景有关药剂师主导的护理过渡(TOC)方法的影响的数据尚未得到充分证实。本试点研究的目的是评估药剂师主导的 TOC 增强型工作流程对住院时间(LOS)和 30 天再入院率(HRR)的影响。结果在内科楼层接受入院药物对账(AMR)和出院药物对账(DMR)的患者的中位住院日(4 天 [3-8])明显低于未接受入院药物对账的患者(7 天 [4-20])(P <0.001)。心脏科楼层的中位住院日在统计学上没有明显影响-3 天(1.75-8)对 3 天(1-8)(P = 0.736)。然而,调整干预次数后的多变量线性回归模型显示,两层楼的 LOS 在统计学上均显著降低;AMR 是降低内科楼层 LOS 的独立风险因素(B = -8.37 [95 CI -11.37 to -5.36],P = .001),也是降低心脏楼层 LOS 的独立风险因素(B = -2.76 [95 CI -5.23 to -0.28],P = 0.029)。在内科楼层,30 天 HRR 没有差异,但在心脏楼层,仅接受 DMR 的患者(12.9%)在数字上低于未接受 DMR 的患者(17.2%)(P = 0.476)。然而,调整干预次数后进行的多变量逻辑回归分析表明,药剂师指导的 AMR 和 DMR 在数量上与 30 天 HRR 的较低比率相关,各自的几率比为 0.64 (95% CI 0.3-1.38) 和 0.83 (95% CI 0.4-1.9) (P = 0.83),在心内科楼层分别为 0.96 (95% CI 0.3-2.6) 和 0.7 (95% CI 0.3-1.8) (P = 0.28)。此外,描述的药剂师主导的 TOC 方法对医院医疗成本的影响是可量化的,反映出在内科楼层,执行 TOC 的中位药物使用成本为 1142.95 美元(639.69-2444.88),而不执行 TOC 的中位药物使用成本为 1371.54 美元(402.92-4277.39)(P <0.001);在外科楼层,中位药物使用成本为 4728.98 美元(2436.66-6846.结论以药剂师为主导的 TOC 干预(特别是 AMR)显著降低了内科和心内科楼层的 LOS,而 AMR 和 DMR 则有望预测所研究楼层 30 天 HRR 的下降。此外,在所研究的两个楼层中,TOC 干预措施普遍对财务产生了显著的影响。
Impact of pharmacist-led transitions of care model on length of hospital stay and 30-day readmission rates at a quaternary care hospital: A pilot study
Background
Data about the impact of pharmacist-led transitions of care (TOC) approach are not well established.
Objectives
The objective of this pilot study was to evaluate the impact of pharmacist-led TOC enhanced workflow on the length of hospital stay (LOS) and the 30-day hospital readmission rates (HRRs).
Methods
This is a quality improvement pilot project conducted at a quaternary care hospital in the United Arab Emirates over 6 weeks on a medical floor and 4 weeks on a cardiac floor. TOC was defined as admission medication reconciliation (AMR) and discharge medication reconciliation (DMR).
Results
The median LOS was statistically significantly lower in patients who received AMR on the medical floor (4 days [3-8]) than those who did not (7 days [4-20]) (P < 0.001). The median LOS on the cardiac floor was not statistically significantly affected—3 (1.75-8) versus 3 (1-8) (P = 0.736). However, the multivariate linear regression model, adjusting for the number of interventions, indicated that LOS was statistically significantly lower on both floors; AMR was an independent risk factor for reducing the LOS on the medical floor (B = −8.37 [95 CI −11.37 to −5.36], P = .001) and on the cardiac floor (B = −2.76 [95% CI −5.23 to −0.28], P = 0.029). The 30-day HRR was not different on the medical floor but was numerically lower on the cardiac floor in patients who received DMR alone (12.9%) than in those who did not (17.2%) (P = 0.476). However, the multivariate logistic regression analysis, adjusting for number of interventions, indicated that the pharmacist-led AMR and DMR combined were numerically associated with lower rates of 30-day HRR with respective odds ratios of 0.64 (95% CI 0.3–1.38) and 0.83 (95% CI 0.4–1.9) (P = 0.83) on the medical floor and of 0.96 (95% CI 0.3–2.6) and 0.7 (95% CI 0.3–1.8) (P = 0.28) on the cardiac floor. In addition, the impact of the described pharmacist-led TOC approach on health care costs at the hospital was quantifiable and reflected a median medications utilization cost of $1142.95 (639.69-2444.88) when TOC is performed versus $1371.54 (402.92-4277.39) without TOC (P < 0.001) on the medical floor and of $4728.98 (2436.66-6846.34) versus $5252.79 (3907.63-7784.57) (P < 0.001) on the cardiac floor throughout the study time period.
Conclusion
Pharmacist-led TOC interventions, specifically AMR, significantly reduced the LOS on the medical and the cardiac floors, whereas both AMR and DMR represented promising predictors of decreased 30-day HRR on the studied floors. Furthermore, the TOC interventions were generally associated with a statistically significant financial impact on both studied floors.